Combinational Therapy in Triple Negative Breast Cancer (eBook)
276 Seiten
Elsevier Science (Verlag)
978-0-323-96137-0 (ISBN)
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level with a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance; combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making essential to understand more about multiple therapies options.
The book is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer.
- Presents up to date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects, and treatment options
- Discusses novel targets and pathways involved in TNBC
- Provides insights and approaches for future research on TNBC
Dr. Manzoor Ahmad Mir holds Master's Degree in Zoology from HNBG Central University and after qualifying prestigious National level CSIR-JRF-NET examination he worked jointly for his Ph. D at Jawaharlal Nehru University New Delhi and CSIR-Institute of Microbial Technology Chandigarh in the field of Immunology. His basic research interests include Cancer Biology, Combination therapy in Breast Cancer, molecular immunology and Tuberculosis immunology. He has published more than 50 high-impact research papers and book chapters, in recognition of which he has received several awards and Royalties from international publishing houses. Dr. Manzoor has authored more than 15 books with international publishers like Elsevier USA and Nova Science Publisher USA, Bentham Sciences, IGI Global, Springer-Nature. He is on the editorial board and Reviewer of some prestigious journals like DOVE medical press, Springer Plus, Cancer Biomarkers, Frontiers, Plos etc and has been an invited speaker at various scientific meetings/conferences within India and abroad. He is member of many scientific organizations and societies like American Association of Cancer Research, Fellow of Royal British Society, International Immunology Association, Indian Cancer Society, Indian Immunology Society, Indian National Science Association, IMMUNOCON etc. Dr Manzoor was awarded Teachers Associate Research Excellence Fellowship (TARE) by DST Govt of India. He has been awarded Summer Research Fellowship Programme (SRFP-2019) by Indian Academy of Sciences and National Science Academy. He was awarded a research project on combination therapy in breast cancer by J&K Science Technology and Innovation. Dr Manzoor has developed Massive Open Online Course (MOOCs) in Immunology course and Endocrinology course for UG students sanctioned by UGC-Consortium for Educational Communication (CEC) SWAYAM Ministry of HRD Govt of India. He has research and teaching experience of 15 years. He currently teaches Cancer Biology, and Immunology at the Department of Bioresources, School of Biological Sciences, University of Kashmir. He is presently heading the Department of Bioresources, University of Kashmir.
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options. The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer. Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options Discusses novel targets and pathways involved in TNBC Provides insights and approaches for future research on TNBC
Erscheint lt. Verlag | 12.5.2022 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
Technik | |
ISBN-10 | 0-323-96137-1 / 0323961371 |
ISBN-13 | 978-0-323-96137-0 / 9780323961370 |
Haben Sie eine Frage zum Produkt? |
Größe: 5,4 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich